Ginkgo Bioworks Holdings (DNA) Net Income towards Common Stockholders (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$6.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 14.63% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$228.3 million (up 41.27% YoY) and the FY2025 annual result came in at -$312.8 million, up 42.83% from the prior year.
• Net Income towards Common Stockholders advanced to -$6.5 million in Q1 2026, from -$80.8 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$6.5 million in Q1 2026 to a low of -$670.6 million in Q2 2022.
• A 5-year average of -$222.4 million and a median of -$173.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 1131.22% — and 2025, when it soared 95.39%.
• Tracing DNA's Net Income towards Common Stockholders over 5 years: stood at -$173.1 million in 2022, then fell by 22.31% to -$211.7 million in 2023, then surged by 49.2% to -$107.5 million in 2024, then gained by 24.91% to -$80.8 million in 2025, then surged by 91.92% to -$6.5 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$6.5 million (Q1 2026), -$80.8 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.